US Oncology ResearchLLC

1. GlaxoSmithKline, LLC. $1,623,323 645 payments
2. Merck Sharp & Dohme Corporation $1,477,936 173 payments
3. TESARO, Inc. $194,900 90 payments
4. Organon LLC $14,870 4 payments

1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter S $528,942 335 payments
2. A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and S $454,281 130 payments
3. A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced,Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy KEYNOTE-181 $346,621 18 payments
4. Dreamm 7: A Multicenter, Open-Label, Randomized Phase III Study to Eva $293,743 86 payments
5. A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab MK3475 in newly diagnosed and treatment naive Multiple Myeloma KEYNOTE 185. $285,293 28 payments
6. A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE-426 $218,458 9 payments
7. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-022, An Anti-Tim-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors $194,900 90 payments
8. A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab $143,710 5 payments
9. A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. $133,014 27 payments
10. A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician s Choice for Metastatic Triple Negative Breast Cancer mTNBC - KEYNOTE-119 $115,952 29 payments

1. Patient care $14,870 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.